Skip to main content
Erschienen in: Journal of Nuclear Cardiology 4/2017

01.08.2017 | Editorial

Sex difference in cardiac metabolism in nonischemic heart failure: Insight for prognostic value of altered cardiac metabolism

verfasst von: Hyung-Jun Im, MD, PhD, Gi Jeong Cheon, MD, PhD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Excerpt

Heart has the highest metabolic demands than any other organs. To maintain contractile function of the heart, constant and rapid production of adenosine triphosphate (ATP) is needed. Fatty acid (FA) and glucose are the main fuels for production of the ATPs by mitochondrial oxidative phosphorylation. In normal condition, 60% to 90% of total ATP is made from FA and the other from glucose or lactate. In a failing heart, cardiac metabolism is profoundly altered, and majority of the studies suggest that FA metabolism decreases. However, it is not clear and still in controversy whether the alteration in cardiac metabolism in a failing heart is an adaptation or maladaptation.13
Literatur
1.
Zurück zum Zitat Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: Implications beyond ATP production. Circ Res 2013;113:709-24.CrossRef Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: Implications beyond ATP production. Circ Res 2013;113:709-24.CrossRef
2.
Zurück zum Zitat Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-129.CrossRef Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-129.CrossRef
4.
Zurück zum Zitat Duvernoy CS, Meyer C, Seifert-Klauss V, Dayanikli F, Matsunari I, Rattenhuber J, et al. Gender differences in myocardial blood flow dynamics: Lipid profile and hemodynamic effects. J Am Coll Cardiol 1999;33:463-70.CrossRef Duvernoy CS, Meyer C, Seifert-Klauss V, Dayanikli F, Matsunari I, Rattenhuber J, et al. Gender differences in myocardial blood flow dynamics: Lipid profile and hemodynamic effects. J Am Coll Cardiol 1999;33:463-70.CrossRef
5.
Zurück zum Zitat Paul DS, Grevengoed TJ, Pascual F, Ellis JM, Willis MS, Coleman RA. Deficiency of cardiac Acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by rapamycin. Biochim Biophys Acta 2014;1841:880-7.CrossRef Paul DS, Grevengoed TJ, Pascual F, Ellis JM, Willis MS, Coleman RA. Deficiency of cardiac Acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by rapamycin. Biochim Biophys Acta 2014;1841:880-7.CrossRef
6.
Zurück zum Zitat Abdurrachim D, Luiken JJ, Nicolay K, Glatz JF, Prompers JJ, Nabben M. Good and bad consequences of altered fatty acid metabolism in heart failure: Evidence from mouse models. Cardiovasc Res 2015;106:194-205.CrossRef Abdurrachim D, Luiken JJ, Nicolay K, Glatz JF, Prompers JJ, Nabben M. Good and bad consequences of altered fatty acid metabolism in heart failure: Evidence from mouse models. Cardiovasc Res 2015;106:194-205.CrossRef
7.
Zurück zum Zitat Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013;1:93-102.CrossRef Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013;1:93-102.CrossRef
8.
Zurück zum Zitat Peterson LR, Soto PF, Herrero P, Schechtman KB, Dence C, Gropler RJ. Sex differences in myocardial oxygen and glucose metabolism. J Nucl Cardiol 2007;14:573-81.CrossRef Peterson LR, Soto PF, Herrero P, Schechtman KB, Dence C, Gropler RJ. Sex differences in myocardial oxygen and glucose metabolism. J Nucl Cardiol 2007;14:573-81.CrossRef
9.
Zurück zum Zitat Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging 2008;1:424-33.CrossRef Peterson LR, Soto PF, Herrero P, Mohammed BS, Avidan MS, Schechtman KB, et al. Impact of gender on the myocardial metabolic response to obesity. JACC Cardiovasc Imaging 2008;1:424-33.CrossRef
10.
Zurück zum Zitat Luptak I, Yan J, Cui L, Jain M, Liao R, Tian R. Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress. Circulation 2007;116:901-9.CrossRef Luptak I, Yan J, Cui L, Jain M, Liao R, Tian R. Long-term effects of increased glucose entry on mouse hearts during normal aging and ischemic stress. Circulation 2007;116:901-9.CrossRef
11.
Zurück zum Zitat Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005;112:2339-46.CrossRef Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005;112:2339-46.CrossRef
12.
Zurück zum Zitat Im HJ, Paeng JC, Cheon GJ, Kim EE, Lee JS, Goo JM, et al. Feasibility of simultaneous 18F-FDG PET/MRI for the quantitative volumetric and metabolic measurements of abdominal fat tissues using fat segmentation. Nucl Med Commun 2016. Im HJ, Paeng JC, Cheon GJ, Kim EE, Lee JS, Goo JM, et al. Feasibility of simultaneous 18F-FDG PET/MRI for the quantitative volumetric and metabolic measurements of abdominal fat tissues using fat segmentation. Nucl Med Commun 2016.
13.
Zurück zum Zitat Uribarri J, Cai W, Woodward M, Tripp E, Goldberg L, Pyzik R, et al. Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: A link between healthy and unhealthy obesity? J Clin Endocrinol Metab 2015;100:1957-66.CrossRef Uribarri J, Cai W, Woodward M, Tripp E, Goldberg L, Pyzik R, et al. Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: A link between healthy and unhealthy obesity? J Clin Endocrinol Metab 2015;100:1957-66.CrossRef
14.
Zurück zum Zitat Iacobellis G, Zaki MC, Garcia D, Willens HJ. Epicardial fat in atrial fibrillation and heart failure. Horm Metab Res 2014;46:587-90.CrossRef Iacobellis G, Zaki MC, Garcia D, Willens HJ. Epicardial fat in atrial fibrillation and heart failure. Horm Metab Res 2014;46:587-90.CrossRef
15.
Zurück zum Zitat Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 2015;11:363-71.CrossRef Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 2015;11:363-71.CrossRef
16.
Zurück zum Zitat Schulz G, von Dahl J, Kaiser HJ, Koch KC, Sabri O, Banneitz L, et al. Imaging of beta-oxidation by static PET with 14(R,S)-[18F]-fluoro-6-thiaheptadecanoic acid (FTHA) in patients with advanced coronary heart disease: A comparison with 18FDG-PET and 99Tcm-MIBI SPET. Nucl Med Commun 1996;17:1057-64.CrossRef Schulz G, von Dahl J, Kaiser HJ, Koch KC, Sabri O, Banneitz L, et al. Imaging of beta-oxidation by static PET with 14(R,S)-[18F]-fluoro-6-thiaheptadecanoic acid (FTHA) in patients with advanced coronary heart disease: A comparison with 18FDG-PET and 99Tcm-MIBI SPET. Nucl Med Commun 1996;17:1057-64.CrossRef
17.
Zurück zum Zitat DeGrado TR, Kitapci MT, Wang S, Ying J, Lopaschuk GD. Validation of 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: Effects of hypoxia and composition of exogenous fatty acids. J Nucl Med 2006;47:173-81.PubMed DeGrado TR, Kitapci MT, Wang S, Ying J, Lopaschuk GD. Validation of 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: Effects of hypoxia and composition of exogenous fatty acids. J Nucl Med 2006;47:173-81.PubMed
18.
Zurück zum Zitat Shoup TM, Elmaleh DR, Bonab AA, Fischman AJ. Evaluation of trans-9-18F-fluoro-3,4-methyleneheptadecanoic acid as a PET tracer for myocardial fatty acid imaging. J Nucl Med 2005;46:297-304.PubMed Shoup TM, Elmaleh DR, Bonab AA, Fischman AJ. Evaluation of trans-9-18F-fluoro-3,4-methyleneheptadecanoic acid as a PET tracer for myocardial fatty acid imaging. J Nucl Med 2005;46:297-304.PubMed
19.
Zurück zum Zitat Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1996;37:1723-30. Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1996;37:1723-30.
Metadaten
Titel
Sex difference in cardiac metabolism in nonischemic heart failure: Insight for prognostic value of altered cardiac metabolism
verfasst von
Hyung-Jun Im, MD, PhD
Gi Jeong Cheon, MD, PhD
Publikationsdatum
01.08.2017
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 4/2017
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-016-0489-0

Weitere Artikel der Ausgabe 4/2017

Journal of Nuclear Cardiology 4/2017 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.